Abstract
Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease. Recently it was reported that interleukin 10 (IL-10) is also overexpressed in skin lesions of atopic dermatitis (AD) patients and this ectopic expression is believed to be an important factor in the pathogenesis of the disease. Thus the regulation of IL-10 production is a potential solution for immunotherapeutic intervention in AD. In this study, we determined whether the tellurium immunomodulating compound, ammonium tri-chloro(dioxoethylene-O,O′-) tellurate (AS101) may inhibit IL-10, and thereby affect the profile of cytokines produced by T cells of AD patients. Further, we investigated the possible correlation between changes in IL-10 levels and the expression of mitogen-activated protein (MAP) kinases. We show here that the IL-10 level was higher in AD patients compared to healthy donors, while their IL-2 and IFNγ levels were reduced. The addition of the AS101 inhibited the production of interleukin-10, while increasing the production of IL-2 and IFNγ. These changes correlate with the inhibition of p38 MAP kinase. The immunomodulatory effect of AS101, together with its excellent clinical safety profile in humans, suggests that AS101 has potential as a therapeutic agent for AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
